ArticleNPJ precision oncology2026

AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers.

Masaki Ishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.